TAK heads into its July 30 earnings release with options positioning at its most aggressively bullish in a year.
The clearest signal is in the options market. The put/call ratio has collapsed to 0.0085 — near the 52-week low of 0.0039 and far below the 20-day average of 0.16. That means call buyers are overwhelming put buyers by a ratio of roughly 120-to-1, an unusually one-sided tilt heading into a major catalyst. It's worth noting this extreme is partly structural for TAK's ADR options, but the direction of travel is unambiguous: investors are not hedging this print, they're positioning for upside.
The borrow market tells a completely different story — one of near-zero short pressure. Availability is exceptionally loose at 1,880%, meaning there are roughly nineteen lendable shares for every one currently borrowed. Cost to borrow has fallen by nearly half over the past month to just 0.25%. The short score has also eased to 29.5, down from 31.5 two weeks ago. None of this suggests any material short squeeze dynamic. The stock itself has gained about 9% over the past month to $17.24, recovering quietly into the report.
The bull case for Takeda rests on a stabilising pipeline across oncology, gastroenterology, and rare diseases, and on the long-running process of deleveraging the balance sheet inherited from the 2019 Shire acquisition. The EV/EBITDA multiple has drifted lower over the past 30 days — now at 6.8x — which supporters argue represents undemanding value for a diversified pharma franchise. Bears point to weak growth metrics: the factor score on growth is the portfolio's softest pillar, with negative sales growth and a deteriorating five-year EBIT trajectory dragging on the overall scorecard. Analyst coverage is stale — the most recent tracked changes date to 2023 — so the Street is not a live input into this setup. What remains is a dividend score ranked in the 98th percentile, which has attracted and retained a deep institutional base: BlackRock holds 8.6% of shares, with Nomura, Vanguard, and Capital Research all adding modestly in the latest quarter.
On past earnings reactions, recent prints have been muted — the May 2026 result moved the ADR just 1.3% on day one and 1.6% over the following week, while the June 2026 event produced a 1.2% decline with a small recovery by day five. The upcoming print will test whether the step-up in the stock over the past month has priced in a continuation of that steady-state outcome, or whether it demands a more meaningful operational beat to hold the gains.
See the live data behind this article on ORTEX.
Open TAK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
